Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma

Completed

• Conditions: Cancer of Liver
• Interventions: Other: no intervention

• Registration Number: NCT05643833
• Lead Sponsor: Zhejiang University

Brief Summary

This is a large-scale study in China to provide evidence and insights in the role of gender in LT for HCC by analyzing the data of 3769 recipients with HCC registered in the China Liver Transplant Registry.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-01
• Primary Completion: 2022-05-30
• Study Completion: 2022-10-15
• Status Verified: 2022-11
• Study First Submitted: 2022-11-29
• Study First Submitted QC: 2022-11-29
• Last Update Submitted: 2022-11-29
• Study First Posted: 2022-12-09
• Last Update Posted: 2022-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3769

Inclusion Criteria

The patients with liver transplants performed from January 2015 to December 2020, whose clinicopathological data were registered in the CLTR.

Exclusion Criteria

Patients with following features were excluded: with concurrent other malignancies, pathologically-confirmed tumor types other than HCC, such as intrahepatic cholangiocarcinoma (ICC), combined hepatocellular cholangiocarcinoma (cHCC-CC), fibrolamellar hepatocellular carcinoma (FLC) or secondary metastatic tumor; without histological confirmation of HCC for transplantation. The patients who received living donor liver transplantation, split liver transplantation, reduced-size liver transplantation or simultaneous transplantation were also excluded. Next, pediatric patients (<18 years) or senile patients (>65 years) and those patients who died within six months after transplantation were also excluded. Finally, the patients with type-1 and type-2 portal vein tumor thrombus (PVTT), tumor metastasis, having doubtful or contradictory data or missing essential data for analysis, re-transplantation during follow-up time were excluded as well.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Female recipient	no intervention	-
Male donor	no intervention	-
Male recipient	no intervention	-
Female donor	no intervention	-

Primary Outcome Measures

Name	Time	Method
Overall survival	January 2015 to December 2020	the overall survival of liver transplant recipient with HCC

Trial Locations

Locations (1)

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China